The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

JPMorgan Chase, Wells Fargo and BlackRock reported strong quarterly results to kick off earnings season, but concerns linger ...

Here are some of the major companies whose stocks moved on the week’s news.

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

FRIDAY, Oct. 11, 2024 (HealthDay News) -- Facing a nationwide shortage of vital IV fluids after Hurricane Helene knocked out ...

Sanofi said it entered into talks with Clayton Dubilier & Rice to offload a controlling stake in its consumer-health division ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

A California physician accused of gross negligence for attributing a stroke patient's death to the COVID vaccine without any ...

Pfizer is facing a messy showdown this week after an outside bid to revive the company’s post-Covid share plunge took an ...